Archives: Search / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011
Feb 5, 2020 Financial and Business Highlights: Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 second quarter ended December 31, 2019. "For our fiscal 2020 second quarter, strong sales across multiple... More |
Jan 30, 2020 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 second quarter on Wednesday, February 5, 2020, after the market closes. Lannett... More |
Jan 13, 2020 --Company to Commence Commercial Launch Shortly, Under Brand Name NUMBRINO®-- Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA), submitted under the 505(b)(2) regulatory pathway,... More |
Jan 6, 2020 Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Venlafaxine Extended Release (ER) Tablets, 150 mg and 225 mg, USP, and Lidocaine Topical Solution 4%. The... More |
Dec 23, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Butalbital,... More |
Dec 12, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it expects to commence marketing in the coming months a generic version of Adderall XR®, an extended-release mixed salt of a single entity... More |
Dec 4, 2019 --Study Achieves All Primary Endpoints; Company to Set Meeting with FDA Regarding Pivotal Trial Design-- Lannett Company, Inc. (NYSE: LCI) today announced positive results from the first human study evaluating insulin glargine that Lannett is developing with its strategic alliance partners within the... More |
Financial and Business Highlights: Net Sales, Profitability Exceeded Expectations Launched First-to-Market Posaconazole Expanded Pipeline with Significant Future Opportunities: • Levothyroxine... More |
Oct 30, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 first quarter on Wednesday, November 6, 2019, after the market closes. Lannett... More |
Oct 1, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of ADVAIR DISKUS® (Fluticasone... More |